Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Third Harmonic Bio, Inc. (THRD)
NASDAQ:THRD
RESEARCH TOOLSreports
THRD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.18 - $16.94
Previous CloseN/A
Volume85.60K
Average Volume (3M)907.92K
Market Cap
$161.31M
Enterprise Value$267.16M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.01
Next Earnings
Mar 26, 2025EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding45,058,414
10 Day Avg. Volume2,156,102
30 Day Avg. Volume907,925
Standard Deviation0.25
R-Squared0.18
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.63K
Enterprise Value/Ebitda-5.41
Forecast
1Y Price Target
$10.13Price Target Upside182.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Financial PositionTHRD has a strong balance sheet to support operations through plans outlined on call.
Potential In Mast Cell DisordersThere may be an opportunity to evaluate THB335 at moderate doses in patients with mast cell-mediated disorders such as chronic spontaneous urticaria.
Strategic OpportunitiesThird Harmonic plans to evaluate strategic alternatives and pursue partnership opportunities for THB335 following safety concerns at higher doses.
Bears Say
Restructuring ImpactThe company will restructure by reducing its workforce by 50% and eliminating all programs not related to THB335, creating near-term uncertainty.
Safety Profile ConcernsSafety profile concerns, including reductions in hemoglobin and neutrophils, likely limit the use of higher doses going forward.
Stock DowngradeAnalyst downgrades the stock to Equal-weight due to near-term uncertainty and lowers the price target from $20 to $5.
---
Ownership Overview
37.67% Insiders
11.06% Mutual Funds
30.74% Other Institutional Investors
15.70% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
THRD FAQ
What was Third Harmonic Bio, Inc.’s price range in the past 12 months?
Third Harmonic Bio, Inc. lowest stock price was $3.18 and its highest was $16.94 in the past 12 months.
What is Third Harmonic Bio, Inc.’s market cap?
Third Harmonic Bio, Inc.’s market cap is $161.31M.
When is Third Harmonic Bio, Inc.’s upcoming earnings report date?
Third Harmonic Bio, Inc.’s upcoming earnings report date is Mar 26, 2025 which is in 32 days.
How were Third Harmonic Bio, Inc.’s earnings last quarter?
Third Harmonic Bio, Inc. released its earnings results on Nov 07, 2024. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.299 by -$0.031.
Is Third Harmonic Bio, Inc. overvalued?
According to Wall Street analysts Third Harmonic Bio, Inc.’s price is currently Undervalued.
Does Third Harmonic Bio, Inc. pay dividends?
Third Harmonic Bio, Inc. does not currently pay dividends.
What is Third Harmonic Bio, Inc.’s EPS estimate?
Third Harmonic Bio, Inc.’s EPS estimate is -0.36.
How many shares outstanding does Third Harmonic Bio, Inc. have?
Third Harmonic Bio, Inc. has 45,058,414 shares outstanding.
What happened to Third Harmonic Bio, Inc.’s price movement after its last earnings report?
Third Harmonic Bio, Inc. reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.299. Following the earnings report the stock price went up 4.974%.
Which hedge fund is a major shareholder of Third Harmonic Bio, Inc.?
Currently, no hedge funds are holding shares in THRD
---
Third Harmonic Bio, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.13 (182.96% Upside)
$10.13 (182.96% Upside)
Blogger Sentiment
Bullish
THRD Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $14.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.20%
12-Months-Change
Fundamentals
Return on Equity
-13.81%
Trailing 12-Months
Asset Growth
7.88%
Trailing 12-Months
Company Description
Third Harmonic Bio, Inc.
Third Harmonic Bio Inc is a clinical-stage company developing a novel oral approach to the treatment of severe allergy and inflammation. The company's lead product candidate, THB001, is a highly selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.
---
THRD Stock 12 Month Forecast
Average Price Target
$10.13
▲(182.96% Upside)
Technical Analysis
Akero Therapeutics
―
IGM Biosciences
―
Cabaletta Bio
―
Immunovant
―
ALX Oncology Holdings
―
Best Analysts Covering THRD
1 Year
1 Year Success Rate
3/8 ratings generated profit
1 Year Average Return
+5.24%
reiterated a buy rating 12 days ago
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of +5.24% per trade.
---